Engineered T cells targeting LMP1 in EBV-positive NPC cells have also demonstrated increased IFN-γ and IL-2 production, effectively killing LMP1-overexpressing NPC cells in vitro and reducing tumour growth in vivo (73, 74). The gene discussed is PDLIM7; the disease is neoplasm.